Home › Companies › Atea Pharmaceuticals, Inc. › 2025-2026

Atea Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Atea Pharmaceuticals, Inc.’s Form 8-K, filed June 22, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

5Ballot items
133Asset managers
903Fund votes
June 18, 2026Meeting date

Results at a glance

Meeting of June 18, 2026: 5 items on Atea Pharmaceuticals, Inc.’s Form 8-K, filed June 22, 2026: 5 without a stated outcome.

Material dissent

Elect Director: Jerome Adams, MD, MPH 56% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Atea Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Atea Pharmaceuticals, Inc.

These tallies are Atea Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 22, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Atea Pharmaceuticals, Inc. — official shareholder meeting results, meeting held June 18, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Jerome Adams, MD, MPH	28,798,012	--	--	22,275,665	8,669,142	56%	Not verified	—
Elect Director: Howard Berman, PhD	44,466,627	--	--	6,607,050	8,669,142	87%	Not verified	—
Elect Director: Barbara Duncan	43,697,098	--	--	7,376,579	8,669,142	86%	Not verified	—
2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026	58,894,207	783,081	65,531	--	0	99%	Not verified	—
3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers	47,452,759	2,977,290	643,628	--	8,669,142	94%	Not verified	—

Source: Atea Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 22, 2026 — read the filing on EDGAR.

How asset managers voted at the Atea Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 133 asset managers that disclosed a Atea Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Barbara Duncan

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD

FOR: 43,697,098WITHHELD: 7,376,579

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Barbara Duncan

Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Barbara Duncan”): 43,697,098 for, 7,376,579 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 15,171,378 for, 977,238 withheld, 19,545 abstained.

FOR

FOR: 15,171,378ABSTAIN: 19,545WITHHOLD: 977,238

Largest asset managers voting on “Election of Class III Directors: Barbara Duncan” at Atea Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	6,910,099	0	92	For
Vanguard	3,772,340	21	9,965	For
BlackRock	2,883,978	0	0	For
Charles Schwab	596,519	0	0	For
TIAA	241,505	0	0	For
Equitable	109,185	0	75,590	Mixed
American Century	0	0	171,034	Withhold
JPMorgan	157,732	0	0	For
Northern Trust	0	0	144,764	Withhold
Lincoln Financial	105,419	0	4,025	For
Goldman Sachs	0	0	107,065	Withhold
QUANTITATIVE MASTER SERIES LLC	105,742	0	0	For
ALPS ETF Trust	0	0	73,473	Withhold
Brighthouse	34,841	0	38,554	Mixed
Delaware/Macquarie	0	0	70,000	Withhold
MASTER INVESTMENT PORTFOLIO	68,110	0	0	For
T. Rowe Price	65,641	0	0	For
AIG/SunAmerica	0	0	64,063	Withhold
EA Series Trust	49,364	0	0	For
Dimensional	0	0	48,664	Withhold
Voya	0	0	43,138	Withhold
Global X	0	0	30,344	Withhold
Bridge Builder Trust	30,304	0	0	For
Pacific Life	27,265	0	0	For
SEI	0	0	15,000	Withhold

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

2. Elect Director: Howard Berman, PhD

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 44,466,627WITHHELD: 6,607,050

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Howard Berman, PhD

Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Howard Berman, PhD”): 44,466,627 for, 6,607,050 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 15,489,659 for, 658,958 withheld, 19,544 abstained.

FOR

FOR: 15,489,659ABSTAIN: 19,544WITHHOLD: 658,958

Largest asset managers voting on “Election of Class III Directors: Howard Berman, PhD” at Atea Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	6,910,099	0	92	For
Vanguard	3,782,306	20	0	For
BlackRock	2,883,978	0	0	For
Charles Schwab	596,519	0	0	For
TIAA	241,505	0	0	For
Equitable	109,185	0	75,590	Mixed
American Century	0	0	171,034	Withhold
JPMorgan	157,732	0	0	For
Northern Trust	144,764	0	0	For
Lincoln Financial	105,419	0	4,025	For
Goldman Sachs	107,065	0	0	For
QUANTITATIVE MASTER SERIES LLC	105,742	0	0	For
ALPS ETF Trust	0	0	73,473	Withhold
Brighthouse	34,841	0	38,554	Mixed
Delaware/Macquarie	0	0	70,000	Withhold
MASTER INVESTMENT PORTFOLIO	68,110	0	0	For
T. Rowe Price	65,641	0	0	For
AIG/SunAmerica	0	0	64,063	Withhold
EA Series Trust	49,364	0	0	For
Dimensional	0	0	48,664	Withhold
Voya	0	0	43,138	Withhold
Global X	30,344	0	0	For
Bridge Builder Trust	30,304	0	0	For
Pacific Life	27,265	0	0	For
SEI	15,000	0	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

3. Elect Director: Jerome Adams, MD, MPH

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

56% Majority: yes · of votes cast

FOR 56%WITHHELD

FOR: 28,798,012WITHHELD: 22,275,665

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: Election of Class III Directors: Jerome Adams, MD, MPH

Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jerome Adams, MD, MPH”): 28,798,012 for, 22,275,665 withheld, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 56% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 7,967,190 for, 7,321,828 withheld, 879,143 abstained.

FORWITHHOLD

FOR: 7,967,190ABSTAIN: 879,143WITHHOLD: 7,321,828

Largest asset managers voting on “Election of Class III Directors: Jerome Adams, MD, MPH” at Atea Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
Fidelity	1,475,271	0	5,434,920	Mixed
Vanguard	3,772,290	71	9,965	For
BlackRock	2,092,540	791,438	0	Mixed
Charles Schwab	0	0	596,519	Withhold
TIAA	0	0	241,505	Withhold
Equitable	109,185	0	75,590	Mixed
American Century	0	0	171,034	Withhold
JPMorgan	157,732	0	0	For
Northern Trust	0	0	144,764	Withhold
Lincoln Financial	105,419	0	4,025	For
Goldman Sachs	0	0	107,065	Withhold
QUANTITATIVE MASTER SERIES LLC	105,742	0	0	For
ALPS ETF Trust	0	0	73,473	Withhold
Brighthouse	34,841	0	38,554	Mixed
Delaware/Macquarie	0	0	70,000	Withhold
MASTER INVESTMENT PORTFOLIO	0	68,110	0	Abstain
T. Rowe Price	0	0	65,641	Withhold
AIG/SunAmerica	0	0	64,063	Withhold
EA Series Trust	49,364	0	0	For
Dimensional	0	0	48,664	Withhold
Voya	0	0	43,138	Withhold
Global X	0	0	30,344	Withhold
Bridge Builder Trust	30,304	0	0	For
Pacific Life	27,265	0	0	For
SEI	0	0	15,000	Withhold

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

4. 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 47,452,759AGAINST: 2,977,290

Details: description as filed, official tally, votes by 133 asset managers

Description as filed by funds: Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Company.

Atea Pharmaceuticals, Inc.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 47,452,759 for, 2,977,290 against, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 46 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at Atea Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	6,910,191	0	0	For
Vanguard	3,779,029	3,294	3	For
BlackRock	2,883,978	0	0	For
Charles Schwab	596,519	0	0	For
TIAA	241,505	0	0	For
Equitable	184,775	0	0	For
American Century	0	171,034	0	Against
JPMorgan	157,732	0	0	For
Northern Trust	144,764	0	0	For
Lincoln Financial	105,419	4,025	0	For
Goldman Sachs	107,065	0	0	For
QUANTITATIVE MASTER SERIES LLC	105,742	0	0	For
ALPS ETF Trust	73,473	0	0	For
Brighthouse	66,198	0	7,197	Mixed
Delaware/Macquarie	70,000	0	0	For
MASTER INVESTMENT PORTFOLIO	68,110	0	0	For
T. Rowe Price	65,641	0	0	For
AIG/SunAmerica	64,063	0	0	For
EA Series Trust	49,364	0	0	For
Dimensional	0	48,664	0	Against
Voya	43,138	0	0	For
Global X	0	30,344	0	Against
Bridge Builder Trust	30,304	0	0	For
Pacific Life	27,265	0	0	For
SEI	0	15,000	0	Against

Fund voting reports, all 46 managers: 15,839,944 for, 321,017 against, 7,200 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 101 asset managers voting on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive officers of the Comp” at Atea Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
Fidelity	11,949,866	0	For
BlackRock	2,241,761	12,745	For
Bain Capital Life Sciences Investors, LLC	2,210,339	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,731,410	0	For
State Street	1,111,831	19,700	For
ACADIAN ASSET MANAGEMENT LLC	819,128	0	For
Two Sigma	781,929	0	For
Charles Schwab	596,796	0	For
Renaissance	530,433	0	For
Vanguard	506,811	0	For
Northern Trust	322,462	2,156	For
PARAMETRIC PORTFOLIO ASSOCIATES LLC	260,551	0	For
DE Shaw	251,664	0	For
Nuveen	243,103	0	For
American Century	0	171,034	Against
Wellington	0	143,567	Against
T. Rowe Price	143,096	0	For
Dimensional	0	136,454	Against
AllianceBernstein	121,320	0	For
MELLON INVESTMENTS Corp	114,880	0	For
STATE OF WISCONSIN INVESTMENT BOARD	98,713	0	For
STRS OHIO	96,400	0	For
Aldebaran Capital, LLC	0	88,935	Against
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	77,902	0	For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST	70,000	0	For

Institutional-manager reports, all 101 managers: 24,694,826 for, 809,299 against. Showing the 25 largest; see all in the interactive database.

5. 2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the…

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 58,894,207AGAINST: 783,081

Details: description as filed, official tally, votes by 46 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Atea Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026”): 58,894,207 for, 783,081 against, per its Form 8-K filed June 22, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 46 asset managers below reported 16,160,961 for, 3 against, 7,197 abstained.

FOR

FOR: 16,160,961AGAINST: 3ABSTAIN: 7,197

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCA” at Atea Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Fidelity	6,910,191	0	0	For
Vanguard	3,782,323	3	0	For
BlackRock	2,883,978	0	0	For
Charles Schwab	596,519	0	0	For
TIAA	241,505	0	0	For
Equitable	184,775	0	0	For
American Century	171,034	0	0	For
JPMorgan	157,732	0	0	For
Northern Trust	144,764	0	0	For
Lincoln Financial	109,444	0	0	For
Goldman Sachs	107,065	0	0	For
QUANTITATIVE MASTER SERIES LLC	105,742	0	0	For
ALPS ETF Trust	73,473	0	0	For
Brighthouse	66,198	0	7,197	Mixed
Delaware/Macquarie	70,000	0	0	For
MASTER INVESTMENT PORTFOLIO	68,110	0	0	For
T. Rowe Price	65,641	0	0	For
AIG/SunAmerica	64,063	0	0	For
EA Series Trust	49,364	0	0	For
Dimensional	48,664	0	0	For
Voya	43,138	0	0	For
Global X	30,344	0	0	For
Bridge Builder Trust	30,304	0	0	For
Pacific Life	27,265	0	0	For
SEI	15,000	0	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

Largest Atea Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 80,027,099 shares outstanding at the time of that meeting.

Fund voting reports: top Atea Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	8.63%
2	Vanguard	4.73%
3	BlackRock	3.60%
4	Charles Schwab	0.75%
5	TIAA	0.30%
6	Equitable	0.23%
7	American Century	0.21%
8	JPMorgan	0.20%
9	Northern Trust	0.18%
10	Lincoln Financial	0.14%

Institutional-manager reports: top Atea Pharmaceuticals, Inc. shareholders by shares voted on “Approval, on an advisory (non- binding) basis, of the compensation of the named executive…”, 2025-2026
#	Asset manager	% of shares outstanding
1	Fidelity	14.93%
2	BlackRock	2.82%
3	Bain Capital Life Sciences Investors, LLC	2.76%
4	GEODE CAPITAL MANAGEMENT, LLC	2.16%
5	State Street	1.41%
6	ACADIAN ASSET MANAGEMENT LLC	1.02%
7	Two Sigma	0.98%
8	Charles Schwab	0.75%
9	Renaissance	0.66%
10	Vanguard	0.63%

Reported Atea Pharmaceuticals, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Atea Pharmaceuticals, Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
FMR (Fidelity)	14.93%	13F
BlackRock	10.54%	13F
BML Investment Partners, L.P.	9.36%	13G
Vanguard Group	5.28%	13F
Two Sigma	2.33%	13F
Geode Capital	2.18%	13F
State Street	2.12%	13F
Dimensional Fund Advisors	1.57%	13F
Renaissance Technologies	1.46%	13F
JPMorgan Chase	1.17%	13F

Percentages above are of 80,027,099 shares outstanding, as reported by Atea Pharmaceuticals, Inc. on its Form 10-Q dated May 11, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Atea Pharmaceuticals, Inc.’s 10-Q dated May 11, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Atea Pharmaceuticals, Inc.'s shareholder meeting held June 18, 2026, in the 2025-2026 proxy season, 133 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 903 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Atea Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 22, 2026.

Atea Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.